Buprenorphine: Difference between revisions

Line 1:

{{MedTemplate

| generic = Buprenorphine

| brand = Suboxone

| brand = Subutex (sublingual; discontinued in US but generic available), Suboxone (buprenorphine + naloxone sublingual film/tablet), Sublocade (monthly SC depot for MOUD), Probuphine (6-month subdermal implant, discontinued 2020), Belbuca (buccal film for pain), Butrans (weekly transdermal patch for pain), Buprenex (IV/IM for acute pain)

| structure =

| classes = Opioid~~, Analgesic~~

| classes = [[:Category:Opioid analgesics|Opioid analgesic (partial mu-agonist, kappa antagonist)]], [[:Category:Schedule III controlled substances|Schedule III controlled substance]]

| ~~mechanism = Partial~~ mu-~~opioid~~ agonist; kappa antagonist

| uses = <vote slug="opioid-use-disorder-bupe-use">Opioid use disorder MOUD (FDA; office-based since 2002)</vote>, <vote slug="moderate-severe-pain-bupe-use">Moderate to severe pain (FDA, Belbuca buccal film + Butrans transdermal patch)</vote>, <vote slug="acute-pain-bupe-use">Acute pain (FDA, Buprenex IV/IM)</vote>, <vote slug="chronic-pain-multimodal-bupe-use">Chronic pain in opioid-tolerant patients with opioid-induced hyperalgesia (off-label rotation)</vote>

| uses =

| starting_dose = MOUD induction (office-based): traditional approach 2-4 mg sublingual after withdrawal score ≥COWS 11-13, then 4-8 mg by end of day 1; titrate to maintenance 8-24 mg/day (typical effective range 16 mg). Bernese microdosing method (avoid precipitated withdrawal): cross-titrate from full agonist with sub-mg buprenorphine doses while continuing full agonist, escalating buprenorphine over 7-10 days. Belbuca buccal pain: 75 mcg-150 mcg every 12 hours; titrate. Butrans transdermal pain: 5 mcg/h patch weekly; titrate. Sublocade depot: 300 mg SC monthly x 2, then 100 mg monthly maintenance.

| starting_dose =

| preparations = Sublingual tablets (Subutex generic) 2, 8 mg; sublingual films (Suboxone) 2/0.5, 4/1, 8/2, 12/3 mg buprenorphine/naloxone; Sublocade SC injection 100 mg, 300 mg pre-filled; Belbuca buccal films 75, 150, 300, 450, 600, 750, 900 mcg; Butrans transdermal patches 5, 7.5, 10, 15, 20 mcg/h (weekly); Buprenex injection 0.3 mg/mL

| preparations =

| fda_max = MOUD: typical effective max 24 mg/day sublingual (doses above offer limited additional mu-occupancy due to ceiling). Pain (Belbuca): 900 mcg every 12 hours.

| fda_max =

| pill_id =

| routes =

| routes = Sublingual (primary for MOUD), buccal (Belbuca for pain), transdermal (Butrans), SC depot (Sublocade), IV/IM (Buprenex). Oral swallowed: very low bioavailability due to first-pass; not therapeutic.

| onset =

| onset = Sublingual analgesic effect 30-60 minutes; MOUD craving suppression within hours; Butrans patch steady-state in 3 days.

| duration =

| duration = MOUD: 24-72 hours per sublingual dose (long; permits every-other-day or three-times-weekly dosing in stable patients); Butrans patch: 7 days; Sublocade depot: 28+ days; Buprenex IV/IM: 6-8 hours.

| halflife =

| halflife = Buprenorphine sublingual: 24-42 hours (long, contributes to extended dosing intervals). Norbuprenorphine (active metabolite, weaker mu-agonist): 24-48 hours.<ref name="suboxone-label">FDA Prescribing Information, Suboxone (buprenorphine/naloxone sublingual film), Indivior, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022410s029lbl.pdf</ref>

| bioavailability =

| bioavailability = ~30% (sublingual; the primary therapeutic route); ~10-20% (oral swallowed, low due to first-pass); ~50% (buccal Belbuca); transdermal Butrans bypasses first-pass.<ref name="suboxone-label" />

| pregnancy =

| pregnancy = Buprenorphine is an increasingly preferred MOUD option in pregnancy alongside methadone; the MOTHER trial (Jones et al 2010 NEJM PMID 21142534) showed comparable maternal outcomes and somewhat milder neonatal abstinence syndrome (NAS) with buprenorphine compared with methadone, supporting either as first-line. Mono-buprenorphine (Subutex) was historically preferred over the naloxone combination (Suboxone) during pregnancy due to naloxone-passage concerns; modern data suggest the combination is also safe and many programs no longer make the distinction. NAS is expected with chronic third-trimester exposure but is typically milder than methadone-NAS. ACOG (Committee Opinion 711) and ASAM endorse buprenorphine as first-line.{{citation needed}}

| legal =

| legal = [[USLegal:Schedule III|Schedule III controlled substance]] in US (lower than methadone's Schedule II, reflecting the partial-agonism ceiling-effect safety profile). The DEA X-waiver requirement for buprenorphine prescribing for OUD was abolished by the Mainstreaming Addiction Treatment (MAT) Act passed December 2022 and implemented in 2023; any DEA-licensed prescriber can now prescribe buprenorphine for OUD without separate waiver, dramatically expanding access. Carries the opioid class '''Boxed Warning''' for respiratory depression with concurrent benzodiazepines or other CNS depressants, addiction/abuse/misuse, and NAS.<ref name="suboxone-label" />

| intro =

| mechanism = <vote slug="buprenorphine-mech-claim">'''Partial mu-opioid receptor agonist''' with high mu-receptor affinity and slow dissociation kinetics. The partial agonism produces a '''ceiling effect''' on respiratory depression (the central distinguishing safety feature from full mu-agonists like methadone, morphine, fentanyl) and on euphoria. The slow dissociation means buprenorphine '''displaces''' other opioids from the mu-receptor (precipitated withdrawal risk in opioid-tolerant patients given buprenorphine while still on full agonists) AND '''blocks''' the effect of subsequently administered opioids (the basis for MOUD-mediated overdose protection). '''Kappa-opioid receptor antagonism''' may contribute to antidepressant and dysphoria-blocking effects. Modest NOP/ORL1 (nociceptin) receptor agonism contributes to the pharmacological profile.</vote> Buprenorphine is a CYP3A4 substrate; norbuprenorphine is the principal active metabolite (also a weak mu-agonist + NOP agonist; substantial accumulation contributes to clinical effect). QTc prolongation is modest, less than methadone, but present and clinically meaningful in overdose.<ref name="suboxone-label" />

| ~~pharmacokinetics~~ =

| intro = Buprenorphine is a partial mu-opioid receptor agonist with kappa-opioid antagonist activity, used primarily as a Schedule III medication for opioid use disorder (MOUD) and secondarily for moderate-to-severe pain. It was synthesized in 1969 at Reckitt and Colman (now Indivior) by John Lewis and colleagues, originally developed as a more potent analgesic alternative to morphine. The 1995 demonstration that buprenorphine could be used to treat opioid use disorder in an office-based outpatient setting (rather than requiring methadone-style Opioid Treatment Program infrastructure) made buprenorphine the foundation of expanded MOUD access in the United States after FDA approval for OUD in 2002. The Drug Addiction Treatment Act of 2000 (DATA 2000) established the X-waiver framework that governed buprenorphine prescribing for OUD until the Mainstreaming Addiction Treatment Act of December 2022 abolished the waiver requirement; as of 2023 any DEA-licensed prescriber can prescribe buprenorphine for OUD. Buprenorphine's defining pharmacological feature is its partial mu-agonism with a ceiling effect on respiratory depression - the same dose that fully occupies the mu-receptor produces less respiratory depression than a full agonist would, substantially improving the overdose-safety profile relative to methadone.

| ~~pharmacodynamics~~ =

| ~~indications~~ =

| history = Buprenorphine was synthesized at the British pharmaceutical company Reckitt and Colman (now Indivior) in 1969 by John Lewis and colleagues, initially as a research compound (designated Reckitt's RX 6029-M) intended as a more potent analgesic than morphine. The partial-agonist character was recognized early in pharmacology studies and was initially considered a drawback for analgesic potency relative to full agonists.

| dosing =

| ~~effects~~ =

FDA approval as Buprenex (IV/IM) for moderate-to-severe acute pain was granted in 1981. The compound was Schedule V at this time, reflecting its low diversion potential in injectable form.

| interactions = <pharmaInteractions/>

| pregnancy_details =

The pivot to MOUD came from a series of clinical trials in the 1990s demonstrating buprenorphine's efficacy in opioid use disorder. Walter Ling, Eric Strain, and others established that buprenorphine could be administered sublingually with weekly or less-frequent dosing in stable patients, contrasting with methadone's daily-witnessed-dosing OTP model.{{citation needed}}

| monitoring =

| counseling =

The Drug Addiction Treatment Act of 2000 (DATA 2000) created the X-waiver framework, allowing physicians to obtain a separate DEA waiver to prescribe buprenorphine for OUD in office-based settings outside the OTP infrastructure. FDA approval of Subutex (buprenorphine sublingual) and Suboxone (buprenorphine/naloxone sublingual) for MOUD followed in 2002. The naloxone in Suboxone is poorly absorbed sublingually (the intended therapeutic route) but is well-absorbed if the tablet is injected, providing a deterrent against diversion to injection.

| anecdotes =

| seealso =

Buprenorphine was rescheduled from V to III in 2002, reflecting recognition of its abuse potential in MOUD-naive populations.

| references =

The Mainstreaming Addiction Treatment (MAT) Act, passed as part of the Consolidated Appropriations Act 2023 in December 2022 and implemented in 2023, abolished the DEA X-waiver requirement. Any DEA-licensed prescriber can now prescribe buprenorphine for OUD without separate certification, removing a major barrier that had been criticized as artificially constraining MOUD access.

Long-acting formulations have expanded the buprenorphine treatment landscape: Probuphine (6-month subdermal implant) was approved 2016 and discontinued 2020; Sublocade (monthly SC depot) was approved 2017 and remains in use; Brixadi (weekly or monthly SC depot) was approved 2023.

| indications = <problem ref="opioid-use-disorder" author="parser-claude">Opioid use disorder; the dominant MOUD option for office-based treatment (no OTP dispensing requirement). Effective for craving suppression, withdrawal management, and overdose-risk reduction via mu-receptor blockade.</problem>

<problem ref="moderate-severe-pain" author="parser-claude">Moderate to severe pain via specific formulations (Belbuca buccal film, Butrans transdermal patch, Buprenex IV/IM).</problem>

<problem ref="chronic-pain" author="parser-claude">Chronic pain in opioid-tolerant patients (off-label rotation), particularly when opioid-induced hyperalgesia is suspected; the partial agonism may attenuate hyperalgesia.</problem>

| dosing = <titration slug="moud-traditional-induction" author="parser-claude" title="MOUD induction (traditional approach)">

Patient must be in mild-to-moderate withdrawal before first dose to avoid precipitated withdrawal (COWS score ≥11-13, typically 12-24 hours after last short-acting opioid, 24-48 hours after last long-acting opioid).

Day 1: 2-4 mg sublingual; observe 60-90 minutes for response and any precipitated withdrawal. Second dose 4 mg if comfortable. Total day 1 typically 8-16 mg.

Day 2: Titrate to comfort, typically 8-16 mg.

Day 3+: Maintenance 8-24 mg/day; typical effective range 16 mg/day.

</titration>

Indicated when patient cannot tolerate withdrawal-period prior to traditional induction, or when transitioning from high-dose full-agonist therapy (e.g., methadone, fentanyl). Patient continues full agonist while starting sub-mg buprenorphine doses, gradually escalating buprenorphine over 7-10 days while tapering off the full agonist.

Sample schedule (variations exist): Day 1: 0.5 mg buprenorphine BID. Day 2-3: 1 mg BID. Day 4-5: 2 mg BID. Day 6-7: 4 mg BID. Day 8+: stop full agonist, continue buprenorphine 8-24 mg/day.

The Bernese approach largely avoids precipitated withdrawal but requires careful patient selection and monitoring.

</titration>

Typical effective dose 8-24 mg/day sublingual. Doses above 24 mg/day produce limited additional mu-receptor occupancy due to the partial-agonist ceiling. Three-times-weekly dosing (e.g., Monday/Wednesday/Friday) is effective in stable patients due to the long half-life and slow receptor dissociation. Sublocade SC depot offers monthly dosing for patients with adherence challenges.

</titration>

Start 75 mcg every 12 hours x 4 days; titrate to 150 mcg q12h. Max 900 mcg q12h. For chronic-pain dosing, NOT MOUD.

</titration>

Start 5 mcg/h patch weekly. Titrate up to 20 mcg/h weekly (max). For chronic-pain dosing in opioid-naive or low-tolerance patients.

</titration>

| effects =

* <effect ref="analgesia" author="parser-claude">Therapeutic effect from partial mu-agonism plus possibly kappa antagonism.</effect>

* <effect ref="craving-suppression" author="parser-claude">The MOUD-specific therapeutic effect; mu-receptor occupancy + slow dissociation block opioid craving and withdrawal.</effect>

* <effect ref="precipitated-withdrawal" author="parser-claude">If buprenorphine is given to an opioid-tolerant patient still substantially mu-receptor-occupied with a full agonist, buprenorphine displaces the full agonist and the receptor is now only partially activated; the abrupt drop in mu-signaling produces severe withdrawal. THE central induction safety concern. Avoided by waiting for moderate spontaneous withdrawal before first dose, or by Bernese microdosing.</effect>

* <effect ref="constipation" author="parser-claude">Less severe than with full agonists but still present.</effect>

* <effect ref="sedation" author="parser-claude">Mild; less than full agonists at equipotent dose due to partial agonism.</effect>

* <effect ref="nausea" author="parser-claude">Common at induction; usually self-limited.</effect>

* <effect ref="sweating" author="parser-claude">Less than methadone but present.</effect>

* <effect ref="dental-caries" author="parser-claude">Sublingual films and tablets associated with elevated dental caries risk (xerostomia + acidic pH of dissolved film). FDA added warning January 2022. Counseling: rinse mouth with water after dissolution, brush teeth, dental visits.</effect>

* <effect ref="hypogonadism" author="parser-claude">Long-term opioid exposure suppresses HPG axis; less severe than full agonists but present.</effect>

* <effect ref="respiratory-depression" author="parser-claude">Present but with CEILING effect; full mu-agonist overdose lethality reduced. Combination with benzodiazepines, alcohol, or other CNS depressants removes the ceiling protection - this is the only combination scenario where buprenorphine overdose mortality approaches full-agonist levels.</effect>

* <effect ref="qt-prolongation" author="parser-claude">Modest; clinically less concerning than methadone but present.</effect>

| pk_absorption = Sublingual ~30% bioavailability (primary therapeutic route). Oral swallowed bioavailability poor (~10-20%) due to extensive first-pass metabolism; not used therapeutically. Buccal (Belbuca) ~50% bioavailability. Transdermal (Butrans) bypasses first-pass entirely; steady-state in ~3 days.<ref name="suboxone-label" />

| pk_distribution = Plasma protein binding ~96% (alpha-1-acid glycoprotein primarily). Highly lipophilic; large volume of distribution. Crosses blood-brain barrier readily and placenta in moderate amounts. Excreted in breast milk at low levels generally compatible with breastfeeding in stable maintained patients.<ref name="suboxone-label" />

| pk_metabolism = Hepatic N-dealkylation primarily via CYP3A4 to norbuprenorphine (active metabolite, weaker mu-agonist + NOP agonist). Also glucuronidation by UGT1A1, UGT1A3, UGT2B7. Norbuprenorphine accumulates with chronic dosing and contributes substantially to clinical effect. Buprenorphine itself is not a clinically significant CYP3A4 inhibitor or inducer.<ref name="suboxone-label" />

| pk_elimination = Primarily fecal/biliary as glucuronide conjugates of parent and metabolites (~70%); urinary ~30%. Half-life sublingual 24-42 hours; norbuprenorphine 24-48 hours. The long half-life supports every-other-day or three-times-weekly dosing in stable MOUD patients.<ref name="suboxone-label" />

| pharmacodynamics = Buprenorphine is a partial mu-opioid agonist with high mu-receptor affinity (Ki ~0.2 nM) and slow dissociation kinetics (receptor residency time hours rather than minutes). The high affinity means buprenorphine displaces lower-affinity opioids from the receptor (the precipitated-withdrawal risk in opioid-tolerant patients) and blocks subsequently administered opioids (the MOUD mu-receptor blockade benefit). The partial agonism means receptor saturation produces less mu-signaling than a full agonist would; this is the basis for the ceiling effect on respiratory depression that distinguishes buprenorphine safety from methadone and other full agonists.

Buprenorphine is also a kappa-opioid receptor antagonist (which may contribute to antidepressant effect and may attenuate stress-induced relapse in OUD) and a partial agonist at the NOP/ORL1 (nociceptin) receptor. The combined receptor profile is distinct from morphine-class full agonists and contributes to the medicine's unique clinical profile.

Norbuprenorphine, the major active metabolite, is itself a partial mu-agonist with lower potency than parent, but accumulates and contributes substantially to net pharmacological effect at steady state.

| interactions = <pharmaInteractions/>

The clinically important interactions for prescribers:

* '''Benzodiazepines + buprenorphine (boxed warning).''' The ceiling effect on respiratory depression is lost when combined with benzodiazepines, alcohol, or other CNS depressants. Concurrent benzo + buprenorphine deaths constitute a substantial fraction of MOUD population mortality. The FDA explicitly does NOT recommend withholding buprenorphine MOUD from patients on benzodiazepines (untreated OUD is more dangerous than benzo-buprenorphine combination), but counseling and benzodiazepine taper should be pursued where feasible.

* '''Full mu-agonist opioids.''' Buprenorphine blocks full-agonist effect at the mu-receptor. Patients on buprenorphine MOUD who require opioid analgesia for acute pain (e.g., post-surgical) need specialist consultation; options include continuing buprenorphine + adding short-acting opioid above the buprenorphine "block," or briefly holding buprenorphine, or using non-opioid alternatives.

* '''CYP3A4 strong inhibitors.''' Ritonavir, clarithromycin, ketoconazole, itraconazole: increase buprenorphine exposure modestly; clinical adjustment usually not required given partial-agonist safety margin.

* '''CYP3A4 strong inducers.''' Rifampin, phenytoin, phenobarbital, carbamazepine, efavirenz, St John's wort: reduce buprenorphine exposure; may need dose increase.

* '''Mixed agonist-antagonists (nalbuphine, butorphanol).''' Precipitate withdrawal in buprenorphine-maintained patients.

* '''Pure antagonists (naloxone, naltrexone).''' Naloxone reverses buprenorphine respiratory depression but high doses or continuous infusion are typically needed due to the high mu-receptor affinity and slow dissociation. Naltrexone administration to a buprenorphine-maintained patient precipitates withdrawal.

* '''QT-prolonging medications.''' Modest additive effect; clinically less concerning than methadone.

* '''Serotonergic medications.''' Buprenorphine has weak SRI activity; serotonin syndrome risk with strong serotonergic medications exists but is less commonly observed than with tramadol or full agonists like meperidine.

| pregnancy_details = Buprenorphine is endorsed by ACOG (Committee Opinion 711) and ASAM as first-line MOUD in pregnancy alongside methadone. The MOTHER trial (Jones HE et al, N Engl J Med 2010, PMID 21142534) compared buprenorphine vs methadone in pregnant women with OUD and found comparable maternal outcomes with somewhat milder neonatal abstinence syndrome (NAS) and shorter NAS treatment duration in the buprenorphine group. The mono-buprenorphine formulation (Subutex generic) was historically preferred in pregnancy over the naloxone combination (Suboxone) due to theoretical concerns about naloxone passage; modern data support both formulations as safe and many programs no longer distinguish.

Buprenorphine clearance may modestly increase during pregnancy; dose adjustment is sometimes needed in the third trimester. Buprenorphine is excreted in breast milk at low concentrations (M/P ratio ~1, but absolute infant exposure is low) and breastfeeding is generally encouraged in stable maintained patients per ACOG and the Academy of Breastfeeding Medicine.

NAS expected with chronic buprenorphine exposure during pregnancy; typically milder and shorter-duration than methadone-NAS; managed in NICU with non-pharmacologic supportive care + opioid taper (morphine or methadone) for severe cases.

| monitoring = '''Boxed warning items:''' respiratory depression (especially with concurrent benzo/CNS depressant), addiction/abuse/misuse, NAS.

'''Specific monitoring:'''

* Pre-induction OUD assessment + COWS scoring before first dose (to confirm withdrawal state, avoid precipitated withdrawal)

* LFTs at baseline + every 6-12 months (buprenorphine hepatotoxicity is rare but documented; monitor especially in hepatitis C coinfected patients)

* PDMP review at intake + regularly per state requirements

* Urine drug screening per program protocol

* Dental examination at intake + annually (FDA 2022 warning regarding sublingual-film dental caries)

* Pregnancy testing in females of reproductive potential at intake; counseling re continuation of MOUD during pregnancy

| counseling = '''Precipitated withdrawal at induction.''' If you take buprenorphine while you still have substantial opioid in your system, you can have severe sudden withdrawal. We will time your first dose to when you are already in moderate withdrawal (or use a microdosing protocol to avoid this).

'''Benzodiazepines and alcohol.''' Buprenorphine has a "ceiling" on respiratory depression that makes it safer than full opioids - BUT this ceiling is lost when you combine buprenorphine with benzodiazepines or alcohol. The combination can be fatal. Talk with your prescriber about any benzodiazepine, sedative, or alcohol use.

'''Acute pain.''' If you need pain medicine for surgery or injury while on buprenorphine, your provider needs to know you are on buprenorphine. The buprenorphine blocks other opioids; managing acute pain requires specialist guidance.

'''Other opioids.''' Buprenorphine blocks the effect of other opioids. If you try to use heroin or other opioids on buprenorphine, you typically won't feel them - this is part of how buprenorphine protects you. Trying to overcome the block with very high doses can produce overdose when the buprenorphine eventually wears off (after stopping treatment).

'''Sublingual administration.''' Place the film or tablet under the tongue and let it dissolve fully (usually 5-10 minutes). Do NOT swallow it - swallowed buprenorphine has very low absorption. Do NOT chew or talk while it dissolves. Rinse your mouth with water after to protect your teeth (FDA dental warning 2022).

'''Driving and machinery.''' Do not drive after the first dose or after any dose increase until you know how buprenorphine affects you. Once stable on a steady dose, most patients can drive safely.

'''Pregnancy.''' Buprenorphine is one of the safest MOUD options during pregnancy. If you become pregnant, do NOT stop abruptly - this can harm the pregnancy. Talk with your provider.

'''Naloxone awareness.''' Keep naloxone (Narcan) available at home; educate household members. Naloxone reverses opioid overdose. Because buprenorphine has high mu-receptor affinity, multiple naloxone doses may be needed; emergency care is essential.

'''Discontinuation.''' Buprenorphine withdrawal is typically milder than full-agonist withdrawal but can be prolonged due to the long half-life. Slow taper recommended; do not stop abruptly after long-term use.

| anecdotes =

| seealso = [[Methadone]], [[Naltrexone]], [[Naloxone]], [[Morphine]], [[Tramadol]]

| references = <references/>

}}

[[Category:Opioid analgesics]]

~~[[Category:Opioids]]~~

[[Category:Schedule III controlled substances]]

~~[[Category:Semisynthetic opioids]]~~

[[Category:Medicines]]

[[Category:~~Analgesics]]~~

~~[[Category:Partial Mu-~~Opioid ~~Agonists~~]]

[[Category:~~Mu-Opioid Receptor Agonists]]~~

~~[[Category:Opioid agonist therapy~~]]

[[Category:~~Anti-addiction agents~~]]

Maintenance script (talk | contribs)